Nasonex (Mometasone Furoate)

Mometasone furoate, the active ingredient in Nasonex, is a corticosteroid presented as a nasal spray for nasal use. It reduces inflammation in the nasal passages and is indicated for allergic rhinitis, seasonal and perennial allergic rhinitis, and nasal polyps in both adults and children, and significantly improves nasal airflow.

GNH USA supplies Nasonex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets.

Nasonex (mometasone furoate) is a topical corticosteroid used to manage inflammatory conditions of the nasal mucosa.

Allergic rhinitis: reduces nasal congestion, itching and sneezing. Seasonal allergic rhinitis: alleviates symptoms triggered by pollen or seasonal allergens. Perennial allergic rhinitis: controls year‑round nasal inflammation. Nasal polyps: decreases polyp size and improves nasal airflow.

Nasonex may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation. - Epistaxis (nosebleeds). - Headache. - Sore throat or cough.

Serious or Rare Side Effects: - Nasal septal perforation. - Severe allergic reaction (anaphylaxis). - Vision changes or cataract formation. - Adrenal suppression with prolonged high‑dose use. - Opportunistic fungal infection of the nasal cavity.

Before using Nasonex, consider the following safety measures.

Pregnancy: consult a healthcare provider as safety data are limited. Pediatric use: follow prescriber guidance for age‑appropriate dosing. Untreated nasal infections: avoid use until infection is resolved. Dosage limits: do not exceed the prescribed number of sprays per day. Adrenal suppression: monitor patients on long‑term high‑dose therapy. Store at room temperature: keep in the original container, protect from moisture and heat.

Nasonex can interact with other medicines that affect corticosteroid activity or metabolism.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use may increase risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local drug exposure.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may modestly increase mometasone levels. - Macrolide antibiotics (e.g., erythromycin): potential for increased systemic absorption. - Ritonavir or other protease inhibitors: may affect metabolism and require monitoring.